These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26352872)

  • 1. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
    Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
    Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
    Di Martino MT; Arbitrio M; Leone E; Guzzi PH; Rotundo MS; Ciliberto D; Tomaino V; Fabiani F; Talarico D; Sperlongano P; Doldo P; Cannataro M; Caraglia M; Tassone P; Tagliaferri P
    Cancer Biol Ther; 2011 Nov; 12(9):780-7. PubMed ID: 21892003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
    Teft WA; Welch S; Lenehan J; Parfitt J; Choi YH; Winquist E; Kim RB
    Br J Cancer; 2015 Mar; 112(5):857-65. PubMed ID: 25611302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.
    Chen S; Laverdiere I; Tourancheau A; Jonker D; Couture F; Cecchin E; Villeneuve L; Harvey M; Court MH; Innocenti F; Toffoli G; Lévesque E; Guillemette C
    Pharmacogenomics J; 2015 Dec; 15(6):513-20. PubMed ID: 25778466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
    De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
    Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
    Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
    J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
    Lévesque E; Bélanger AS; Harvey M; Couture F; Jonker D; Innocenti F; Cecchin E; Toffoli G; Guillemette C
    J Pharmacol Exp Ther; 2013 Apr; 345(1):95-101. PubMed ID: 23386248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in ATP-binding cassette transporter genes and interaction with diet and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study.
    Kopp TI; Andersen V; Tjonneland A; Vogel U
    Scand J Gastroenterol; 2015; 50(12):1469-81. PubMed ID: 26109419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
    Rhodes KE; Zhang W; Yang D; Press OA; Gordon M; Vallböhmer D; Schultheis AM; Lurje G; Ladner RD; Fazzone W; Iqbal S; Lenz HJ
    Drug Metab Lett; 2007 Jan; 1(1):23-30. PubMed ID: 19356014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
    de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
    Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
    Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
    Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
    Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
    Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Sirilerttrakul S; Chamnanphon M; Puangpetch A; Sukasem C
    Sci Rep; 2020 Aug; 10(1):13486. PubMed ID: 32778670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
    Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Matsunaga M; Araki K; Tanaka R; Ichikawa W; Miya T; Narabayashi M; Akiyama Y; Kawara K; Ando Y; Sasaki Y
    Biol Pharm Bull; 2008 Nov; 31(11):2137-42. PubMed ID: 18981587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan pharmacogenetics: influence of pharmacodynamic genes.
    Hoskins JM; Marcuello E; Altes A; Marsh S; Maxwell T; Van Booven DJ; Paré L; Culverhouse R; McLeod HL; Baiget M
    Clin Cancer Res; 2008 Mar; 14(6):1788-96. PubMed ID: 18347181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
    Jada SR; Lim R; Wong CI; Shu X; Lee SC; Zhou Q; Goh BC; Chowbay B
    Cancer Sci; 2007 Sep; 98(9):1461-7. PubMed ID: 17627617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy.
    Treenert A; Areepium N; Tanasanvimon S
    Asian Pac J Cancer Prev; 2018 Oct; 19(10):2757-2764. PubMed ID: 30360603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine.
    Paulík A; Nekvindová J; Filip S
    Tumori; 2020 Apr; 106(2):87-94. PubMed ID: 30514181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.